Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

Biomarker discovery and validation are necessary for improving the prediction of clinical
outcomes and patient monitoring. Despite considerable interest in biomarker discovery and …

Genetic and epigenetic modifications in DNA contribute to altered gene expression in aging
and cancer. In human cancers, epigenetic changes such as DNA methylation, histone …

Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who
respond to poly (ADP-ribose) polymerase inhibitor (PARPi) therapy is of great clinical …

Summary The Cancer Genome Atlas (TCGA) project has analyzed mRNA expression,
miRNA expression, promoter methylation, and DNA copy number in 489 high-grade serous …

High-grade serous ovarian carcinoma presents significant clinical and therapeutic
challenges. Although the traditional model of carcinogenesis has focused on the ovary as a …

Abstract Knowledge of epigenetic alterations in disease is rapidly increasing owing to the
development of genome-wide techniques for their identification. The ever-growing number …

Epigenetics is one of the most promising and expanding fields in the current biomedical
research landscape. Since the inception of epigenetics in the 1940s, the discoveries …

Defects in chromatin modifiers and remodelers have been described both for hematological
and solid malignancies, corroborating and strengthening the role of epigenetic aberrations …

Abstract Poly (ADP‐ribose) polymerase (PARP) inhibitors have provided great clinical
benefits to ovarian cancer patients. To date, three PARP inhibitors, namely, olaparib …